Search Clinical Trials Search
Clinical Trials
× ...
Sort & Filter
Sort by
Specialty

Disease or Condition

Age Group


Drug/Medication


382 results found


Melanoma

Regeneron, R3767-ONC-2466, Ph2, open label, Melanoma, Fianlimab Plus Cemiplimab

Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) ...


Lung

SWOG, S1800E, PhII/III, Randomized, Doetaxel + Ramucirumab +/- Cemiplimab, NSCLC

Primary Objective: The primary objective of the study is to compare overall survival (OS) between participants randomized to docetaxel and ramucirumab with or without cemiplimab (REGN2810) who have acquired resistance to platinum-based chemotherapy and ...